Generic Seasonique Availability

See also: Generic Seasonale

Seasonique is a brand name of ethinyl estradiol/levonorgestrel, approved by the FDA in the following formulation(s):

SEASONIQUE (ethinyl estradiol; levonorgestrel - tablet;oral)

  • Manufacturer: TEVA BRANDED PHARM
    Approval date: May 25, 2006
    Strength(s): 0.03MG,0.01MG;0.15MG,N/A [RLD] [AB]

Has a generic version of Seasonique been approved?

A generic version of Seasonique has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Seasonique and have been approved by the FDA:

DAYSEE (ethinyl estradiol; levonorgestrel tablet;oral)

  • Manufacturer: LUPIN LTD
    Approval date: April 10, 2013
    Strength(s): 0.03MG,0.01MG;0.15MG,N/A [AB]

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet;oral)

  • Manufacturer: WATSON LABS
    Approval date: May 31, 2011
    Strength(s): 0.03MG,0.01MG;0.15MG,N/A [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Seasonique. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
    Patent 7,320,969
    Issued: January 22, 2008
    Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
    Assignee(s): Duramed Pharmaceuticals, Inc.
    This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
    Patent expiration dates:
    • January 30, 2024
      ✓ 
      Patent use: PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
  • Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
    Patent 7,615,545
    Issued: November 10, 2009
    Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
    Assignee(s): Duramed Pharmaceuticals, Inc.
    This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
    Patent expiration dates:
    • June 15, 2023
      ✓ 
      Patent use: PREVENTION OF PREGNANCY
  • Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
    Patent 7,855,190
    Issued: December 21, 2010
    Inventor(s): Bell; Robert G. & Ben-Maimon; Carole S. & Iskold; Beata & Bronnenkant; Lance J. & Hait; Howard & Reape; Kathleen Z.
    Assignee(s): Teva Women's Health, Inc.
    The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
    Patent expiration dates:
    • December 5, 2028
      ✓ 
      Patent use: PREVENTION OF PREGNANCY
  • Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
    Patent 7,858,605
    Issued: December 28, 2010
    Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
    Assignee(s): Teva Women's Health, Inc.
    This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
    Patent expiration dates:
    • June 23, 2023
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web2)